Induction with anti-thymocyte globulin in heart transplantation is associated with better long-term survival compared with basiliximab

Journal of Heart and Lung Transplantation

Volumn 34, Issue 10, 2015, Pages 1283-1291

  Ansari, David ^a   Lund, Lars H ^b   Stehlik, Josef ^c   Andersson, Bodil ^a   Höglund, Peter ^a   Edwards, Leah ^d   Nilsson, Johan ^a  

^a LUND UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d International Society for Heart and Lung Transplantation Transplant Registry   (United States)

Author keywords

anti thymocyte globulin; ATG; basiliximab; cardiovascular related death; graft failure; heart transplantation; infection related death; mortality

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN A; MYCOPHENOLATE MOFETIL; PANEL REACTIVE ANTIBODY; TACROLIMUS; THYMOCYTE ANTIBODY; HYBRID PROTEIN; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CARDIOVASCULAR MORTALITY; FEMALE; GRAFT FAILURE; GRAFT INFECTION; GRAFT RECIPIENT; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INDUCTION THERAPY; INTENSIVE CARE UNIT; LONG TERM SURVIVAL; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONISCHEMIC CARDIOMYOPATHY; PATIENT HISTORY OF TRANSPLANTATION; PRIORITY JOURNAL; RETRANSPLANTATION; CARDIOVASCULAR DISEASES; COMPARATIVE STUDY; COMPLICATION; GRAFT REJECTION; GRAFT SURVIVAL; MORTALITY; PROPORTIONAL HAZARDS MODEL; REGISTER; YOUNG ADULT;

ADULT; ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; CARDIOVASCULAR DISEASES; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RECOMBINANT FUSION PROTEINS; REGISTRIES; YOUNG ADULT;

EID: 84943348562     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2015.04.001     Document Type: Article

References (27)

1. X.M. Mueller Drug immunosuppression therapy for adult heart transplantation. Part 1: immune response to allograft and mechanism of action of immunosuppressants Ann Thorac Surg 77 2004 354 362
2. M.R. Costanzo, A. Dipchand, R. Starling, and et al. The International Society of Heart and Lung Transplantation guidelines for the care of heart transplant recipients J Heart Lung Transplant 29 2010 914 956
3. B. Kaplan, G.J. Burkhart, and F.G. Lakkis Immunotherapy in transplantation Principles and practice 2012 Wiley-Blackwell Hoboken, NJ
4. F. Flaman, S. Zieroth, V. Rao, H. Ross, and D.H. Delgado Basiliximab versus rabbit anti-thymocyte globulin for induction therapy in patients after heart transplantation J Heart Lung Transplant 25 2006 1358 1362
5. M.F. Mattei, M. Redonnet, I. Gandjbakhch, and et al. Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy J Heart Lung Transplant 26 2007 693 699
6. J. Stehlik, L.B. Edwards, A.Y. Kucheryavaya, and et al. The Registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report - 2012 J Heart Lung Transplant 31 2012 1052 1064
7. C.R. Ensor, W.D. Cahoon Jr, M.L. Hess, V. Kasirajan, and R.H. Cooke Induction immunosuppression for orthotopic heart transplantation: a review Prog Transplant 19 2009 333 341 quiz 342
8. A. Aliabadi, M. Grommer, A. Cochrane, O. Salameh, and A. Zuckermann Induction therapy in heart transplantation: where are we now? Transpl Int 26 2013 684 695
9. A. Emin, C.A. Rogers, J. Thekkudan, R.S. Bonser, and N.R. Banner Steering Group, UK Cardiothoracic Transplant Audit. Antithymocyte globulin induction therapy for adult heart transplantation: a UK national study J Heart Lung Transplant 30 2011 770 777
10. A. Andres Cancer incidence after immunosuppressive treatment following kidney transplantation Crit Rev Oncol Hematol 56 2005 71 85
11. M.R. Mehra, M.J. Zucker, L. Wagoner, and et al. A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation J Heart Lung Transplant 24 2005 1297 1304
12. M. Carrier, M.H. Leblanc, L.P. Perrault, and et al. Basiliximab and rabbit anti-thymocyte globulin for prophylaxis of acute rejection after heart transplantation: a non-inferiority trial J Heart Lung Transplant 26 2007 258 263
13. N.K. Chou, S.S. Wang, Y.S. Chen, and et al. Induction immunosuppression with basiliximab in heart transplantation Transplant Proc 40 2008 2623 2625
14. D. Hosmer Jr, S. Lemeshow, and R. Sturdivant Model-building strategies and methods for logistic regression, in applied logistic regression Third edition 2013 John Wiley & Sons, Inc Hoboken, NJ
15. I.R. White, P. Royston, and A.M. Wood Multiple imputation using chained equations: issues and guidance for practice Stat Med 30 2011 377 399
16. B.D. Kahan, P.R. Rajagopalan, and M. Hall Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group Transplantation 67 1999 276 284
17. B. Nashan, R. Moore, P. Amlot, A.G. Schmidt, K. Abeywickrama, and J.P. Soulillou Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group Lancet 350 1997 1193 1198
18. A.C. Webster, E.G. Playford, G. Higgins, J.R. Chapman, and J.C. Craig Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials Transplantation 77 2004 166 176
19. D.C. Brennan, J.A. Daller, K.D. Lake, D. Cibrik, D. Del Castillo Thymoglobulin Induction Study Group Rabbit antithymocyte globulin versus basiliximab in renal transplantation N Engl J Med 355 2006 1967 1977
20. J.F. Regan, C. Lyonnais, K. Campbell, L.V. Smith, and R. Buelow US Thymoglobulin Multi-Center Study Group. Total and active Thymoglobulin levels: effects of dose and sensitization on serum concentrations Transpl Immunol 9 2001 29 36
21. L. Lund, L. Edwards, A. Kucheryavaya, and et al. Registry of the International Society for Heart and Lung Transplantation: 31st official adult heart transplantation report - 2014; focus theme: retransplantation J Heart Lung Transplant 33 2014 996 1008
22. U.S. Department of Health & Human Services. U.S Food and Drug Administration. Basiliximab product approval information - licensing action. Available at: http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/therapeuticbiologicapplications/ucm093365.htm or http://www.fda.gov. Accessed June 2, 2015.
23. L.H. Lund, L.B. Edwards, A.Y. Kucheryavaya, and et al. The Registry of the International Society for Heart and Lung Transplantation: thirtieth official adult heart transplant report - 2013; focus theme: age J Heart Lung Transplant 32 2013 951 964
24. European Medicines Agency. Science Medicines Health. Pharmacovigilance Risk Assessment Committee recommendations on signals. Available at: http://www.ema.europa.eu.
25. U.M. Thiyagarajan, A. Ponnuswamy, and A. Bagul Thymoglobulin and its use in renal transplantation: a review Am J Nephrol 37 2013 586 601
26. A. Beniaminovitz, S. Itescu, K. Lietz, and et al. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody N Engl J Med 342 2000 613 619
27. R.E. Hershberger, R.C. Starling, H.J. Eisen, and et al. Daclizumab to prevent rejection after cardiac transplantation N Engl J Med 352 2005 2705 2713